Mastocytosis. Photo by Doc James via Wikimedia Commons Recent findings show treatment with the selective KIT D816V inhibitor avapritinib for indolent systemic mastocytosis (ISM) improved dermatologic symptoms, decreased skin lesion size, normalized skin lesion colour, and reduced skin mast cell burden. The study was published in the Journal of the American Academy of Dermatology . In a press release , the study’s senior author, Karin Hartmann, MD, said that her mastocytosis patients...

The U.S. Food and Drug Administration (FDA) has released an alert to healthcare professionals and consumers that unsafe counterfeit versions

“We thus expect that epigenetic causes are hidden not only in these but also in other diseases"